首页> 外文期刊>Cell >Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer
【24h】

Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer

机译:非小细胞肺癌分子亚型选择性弱点的系统鉴定

获取原文
获取原文并翻译 | 示例
           

摘要

Context-specific molecular vulnerabilities that arise during tumor evolution represent an attractive intervention target class. However, the frequency and diversity of somatic lesions detected among lung tumors can confound efforts to identify these targets. To confront this challenge, we have applied parallel screening of chemical and genetic perturbations within a panel of molecularly annotated NSCLC lines to identify intervention opportunities tightly linked to molecular response indicators predictive of target sensitivity. Anchoring this analysis on a matched tumorormal cell model from a lung adenocarcinoma patient identified three distinct target/response-indicator pairings that are represented with significant frequencies (6%-16%) in the patient population. These include NLRP3 mutation/inflammasome activation-dependent FLIP addiction, co-occurring KRAS and LKB1 mutation-driven COPI addiction, and selective sensitivity to a synthetic indolotriazine that is specified by a seven-gene expression signature. Target efficacies were validated in vivo, and mechanism-of-action studies informed generalizable principles underpinning cancer cell biology.
机译:在肿瘤进化过程中出现的特定于上下文的分子漏洞代表了有吸引力的干预目标类别。但是,在肺部肿瘤中检测到的体细胞病变的频率和多样性可能会混淆识别这些靶标的工作。为了应对这一挑战,我们在一组带分子注释的NSCLC细胞系中应用了化学和遗传扰动的平行筛选,以识别与预测靶标敏感性的分子反应指标紧密相关的干预机会。将这种分析锚定在来自肺腺癌患者的匹配的肿瘤/正常细胞模型上,确定了三个不同的靶标/反应指标配对,在患者群体中以明显的频率(6%-16%)表示。这些包括NLRP3突变/炎症小体激活依赖性FLIP成瘾,共同发生的KRAS和LKB1突变引起的COPI成瘾,以及对合成吲哚三嗪的选择性敏感性,该敏感性由七个基因的表达特征所指定。靶标功效已在体内得到验证,作用机制研究为癌细胞生物学提供了可推广的普遍原则。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号